# Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

> **NCT07550972** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** A single-arm, single-center clinical trial evaluating efficacy

## Key facts

- **NCT ID:** NCT07550972
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-05-01
- **Primary completion:** 2030-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550972, "Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07550972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*